We are creating new treatments to reverse the progression of disease, improve quality of life, and inform clinical decisions. We are building prescription digital therapeutics that deliver a new kind of behavioral therapy, and creating feedback mechanisms using remotely-monitored and patient-generated data. We will know we are successful when...
People
Improve their health, quality of life, and reduce or eliminate the ongoing need for medications.
Providers
Can prescribe behavioral therapy and get the data they need to improve overall care, when and how they want it.
Payers
Provide access to behavioral therapy resulting in meaningful improvements in their members' lives and reductions in the overall cost of care.
Kevin Appelbaum
Co-founder & CEO
Mark Berman, MD
Chief Medical Officer
Kristin Wynholds
Chief Product Officer
Justin Zamirowski
Chief Commercial Officer
Andres Camacho
Head of Engineering
David Perry
Co-founder & Chairman
Kevin Appelbaum
Co-founder & CEO
Andy Armanino
Board Director
Richard Carmona, MD
Board Director
Risa Lavizzo-Mourey, MD, MBA
Board Director
Geoffrey Parker
Board Director
We are pioneering a prescription digital therapeutics (PDTs) platform for treating cardiometabolic diseases. Our approach holds the potential to enable changes in neural pathways of the brain that leads to lasting behavioral change — and drastically lower the healthcare costs of treating multiple conditions.
We’re honored to welcome a new addition to our team, Alyssa Haigood, who has joined us as a senior financial analyst. Alyssa will contribute to budgeting, forecasting, building financial models and assisting with financial planning for our prescription digital therapeutic (PDT) programs.
